Government provided rating, alleviation of financial constraints, and corporate investment
Accounting & Finance · 2023-12 · 63 (4) · 3763-3779
DOI: 10.1111/acfi.13064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Accounting & Finance, online erschienen am 29.01.2023. Verfasst von Jinyang Li und 2 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Social Science Fund of China.
Abstract (Originalsprache)
The State Taxation Administration (STA) of China established the tax credit rating system in 2015. Together with the banking regulatory authorities, STA entitles the higher‐level firms to favourable bank lending. We find that higher‐level firms are positively associated with capital investment, R&D expenditures and employment. These effects are more pronounced in private firms, small firms, and financially constrained firms. We identify that firms rated higher‐level receive more debt financing at lower cost, and hoard less cash for the precautionary reasons. Our findings highlight the importance of the government rating, especially a developed credit rating market in which is absence in emerging economies.
Förderung
- National Natural Science Foundation of China
- National Social Science Fund of China
Zitieren
APA
Li, J., Wang, J. J., & Yu, M. (2023). Government provided rating, alleviation of financial constraints, and corporate investment. Accounting & Finance, 63(4), 3763-3779. https://doi.org/10.1111/acfi.13064
Vancouver
Li J, Wang JJ, Yu M. Government provided rating, alleviation of financial constraints, and corporate investment. Accounting & Finance. 2023;63(4):3763-3779. doi:10.1111/acfi.13064
BibTeX
@article{Li2023,
author = {Li, Jinyang and Wang, Jenny Jing and Yu, Minggui},
title = {Government provided rating, alleviation of financial constraints, and corporate investment},
journal = {Accounting & Finance},
year = {2023},
volume = {63},
number = {4},
pages = {3763--3779},
doi = {10.1111/acfi.13064}
}
EUVIMED